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SUMMARY 
A limited, but accurate amount of detailed information about the radioactive isotopes 
used in the U.S. for medical procedures was collected from a local hospital and from a 
recent report on the U.S. Radiopharmaceutical Markets.  These data included the total 
number of procedures, the specific types of procedures, the specific radioisotopes used 
in these procedures, and the dosage administered per procedure.  The information from 
these sources was compiled, assessed, pruned, and then merged into a single, 
comprehensive and consistent set of results presented in this report.  A summary of 
these results is given in Table 2-1, and displayed as distributions in Figures 1a and 1b.   
 
The main findings from this preliminary survey are: 
• A total of approximately 14.4 million medical procedures using radioisotopes 
were performed in the U.S. during 2001.   
• Of this total number of procedures during 2001, approximately 14.2 million were 
diagnostic procedures and 0.2 million were therapeutic procedures. 
• Although there were over 45 different commercially-available products used in 
over 75 different types of procedures, there were only 17 different isotopes used 
as radioactive agents in these products.  
• Of these 17 different isotopes, 12 are customarily administered to outpatients, 
and at 91.5 %, the isotope Tc-99m is by an overwhelming margin the most likely 
isotope to be administered. 
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1.0 INTRODUCTION 
1.1 Motivation 
Each day in the U.S., over 39,000 medical procedures are performed that use 
radioactive isotopes.  The overwhelming majority of these procedures are diagnostic in 
nature, and performed on an out-patient basis, i.e., most of these patients are free to 
move about in less than 24 hours after receiving the initial dose.  Within that time period, 
most of these patients, traveling either as pedestrians or as passengers in vehicles, may 
cause alarms in various handheld or roadside radiation detectors.  As local 
governments, as well as the Department of Homeland Security (DHS), Customs and 
Border Protection (CBP), implements their task to detect the illicit transport of nuclear 
material, the presence of radiation detectors will increase.  The information on medical 
isotopes compiled in this survey should help in estimating the frequency and signatures 
of these “innocent” medical-based alarms.   
1.2 Objective 
The objective of this survey was to obtain accurate, up-to-date information about the 
radioactive isotopes used in the U.S. for medical procedures.  The categories of data 
sought were the total number of such procedures, the specific types of procedures, the 
specific radioisotopes used in these procedures, and the dosage administered per 
procedure.  The results presented in this Preliminary Survey do not represent an 
exhaustive search, and thus, should be considered as initial estimates.  However, 
because the data used to obtain these preliminary results was of high quality, the results 
are expected to be reasonably accurate. 
1.3 Data Sources 
The data collected for this Preliminary Survey was obtained from the three sources 
(listed in the Reference section, below).  These sources represent the Medical 
community, the Business & Finance community, and the Applied Nuclear Science 
community.  Because these professions have been compiling information for different 
purposes, data from all three sources were needed to cover the range of our objectives.   
To attain a single, comprehensive and consistent set of data, the information from the 
above three sources was compiled, assessed, pruned, and then merged to give the 
results shown in the body of this report.  This information is used as an initial database 
for estimating the number and characteristic signature of medical incidents that may be 
detected by radiation portal monitors.  
A summary of the Preliminary Survey results is given in Table 1, and displayed as 
distributions in  Figure 2-1.  The sets of data used to obtain this summary are listed in 
Table 2, Table 3, and Table 4 in the Data Tables section at the end of this report.  
Background discussion and more detailed comments about these sets of data are given 
in the Sections 2, 3, and 4 below. 
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2.0 MEDICAL DATA 
The data from the Medical community were obtained from the records of the Nuclear 
Medicine Department of a local hospital in Richland WA (Ref.1).  The period covered by 
these records was from January 01, 2001 through November 23, 2002.  The original 
data were listed in two different types of data records: Statistical Report sheets and 
Exam Master File sheets.  The Statistical Report sheets listed the Exam Types, the 
number of each Exam Type given over the period of the report, and the Patient Type 
(e.g. In-Patient, Out-Patient, etc.).  The Exam Master File sheets listed Exam Reference 
Numbers (Exam R#) for each Exam Type, the Radiopharmaceutical Product used for 
each Exam R#, and the range of activity for each Radiopharmaceutical Product.  The 
data from these original records were cross-referenced, checked for consistency, and 
merged into the set of data listed in Table 2 (listed in the Data Tables section at the end 
of this report). 
From the data listed in Table 2, it is seen a total of 2797 exams were performed on 2694 
patients (i.e., 1.04 exams per patient) over the base-year period of 1 January 2001 – 31 
December 2001.  The breakdown of these exams was 39.24 % male, 58.20 % female, 
and 2.41 % pediatric.  The majority of these exams (91 %) were administered to out 
patients. 
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Table 1: Summary of Prelimary Survey Results 
Isotope 
Average 
Adminis
-tered 
Activity 
(MBq) 
Half Life Organ 
Percent of 
2001 
Dosages at 
local 
hospital 
(2797 Total) 
Percent of 
2002 
Dosages 
at local 
hospital 
(2352 
Total in 11 
months) 
*Percent of  
Procedures 
Administere
d in U.S. 
during 2001 
(14.39 millio
n Total) 
*Annual 
Procedures in 
U.S. per ten 
thousand 
population for 
2001 
C-14 0.0370 5,700 yr Kidneys, 
Bladder 
1.07 1.19 1.89 9.7 
Cs-137 N/A 30.17 yr  0.07 0.04 Not  
Analyzed 
Not Analyzed 
Co-57 0.0222  270 days Bladder, 
Liver, 
Kidneys 
0.61 1.40 1.07 5.5 
Cr-51 2.775 27.7 days Liver 0.25 0.47 0.35 1.8 
F-18 740.0 109 min Bones, 
Bladder 
*1.43 *1.00 2.02 10.3 
Ga-67 370.0 78 hr Intestines, 
Marrow 
0.11 0.34 0.19 1.0 
I-123 11.10 13.3 hrs Thyroid, 
Kidneys 
0.86 5.82 0.03 0.2 
I-125 N/A 60 day Thyroid, 
Spleen, 
Lungs 
0.00 0.00 Insufficient 
Data 
Insufficient 
Data 
I-131 1546.7 8 day Thyroid, 
kidneys 
8.54 5.19 0.34 1.7 
In-111 119.33 68 hrs Liver, 
Marrow, 
Spleen 
0.89 1.49 1.40 7.2 
Rb-82m N/A 6.2 hrs  0.00 0.00 Insufficient 
Data 
Insufficient 
Data 
Sm-153 5180.0 46.8 hrs  0.04 0.04 0.39 2.0 
Sr-89 148.0 50.5 day  0.04 0.00 0.39 2.0 
Tc-99m 625.71 6 hrs Liver, 
Spleen, 
Marrow, 
Kidneys, 
Bladder, 
Stomach, 
Bones 
87.06 83.55 91.51 467.7 
Tl-201 740.00 73.5 hrs Heart, 
Lungs 
0.36 0.43 0.42 2.2 
Xe-133 370.00 5 day Lungs 0.00 0.00 Insufficient 
Data 
Insufficient 
Data 
Y-90 1184.0 64.1 hrs  0.00 0.04 Insufficient 
Data 
Insufficient 
Data 
Footnotes    *Estimated *Estimated *From Market 
Data 
*Using 2000 
Census, 
281.42 million 
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Distribution of Local Hospital Data
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 Figure 2-1: FIGURES 1a(Top) and 1b (Bottom). 
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3.0 BUSINESS & FINANCE DATA 
The data from the Business & Finance community were taken from a recent report by 
Frost & Sullivan entitled “U.S. Radiopharmaceuticals Markets.” (Ref.2). The overall 
objective of this report was to assess the current state of the various sectors of U.S. 
markets, and predict the behavior of the individual market sectors in the near future.  
The data in the report covers the eleven-year period from 1998 through 2008; where the 
2001 data are used as the base year.  The data listed for 2002 – 2008 were extrapolated 
from the earlier data by using reasonably sound economic assumptions, and, depending 
on the particular market sector, amounted to compound annual growth rates from 
approximately 2 % to 6 %.   
Because of the financial perspective of this report, the data from this source is organized 
according to the dominant market sectors, with emphasis on market-place drivers and 
projected revenues.  Medical procedure types define the market sectors, where the 
topmost major division of the overall market is made between Diagnostic and 
Therapeutic procedures.  These two major sectors are further broken down into their 
dominant components of three diagnostic sub- sectors and two therapeutic sub-sectors.  
These sub-sectors are Diagnostic-Cardiac, Diagnostic-PET/FDG, Diagnostic-Other, and 
Therapeutic-Bone and Therapeutic-Thyroid.  All other therapeutic procedures, such as 
brachytherapy seeds (Cesium-137 implants) and Rhenium-188 therapy (following 
vascular stents for prevention of restenosis) were not considered significant for the 
purposes of this report; and thus were omitted.  For each one of the five sub-sectors, we 
were able to obtain (or deduce) from the information in this report data on the total 
number of procedures, the dominant products used for these procedures, and the 
isotope used in each of the products.  This information was distributed throughout the 
report as textual comments or in various tables.  
According to this report, there were a total of 14.19 E+6 Diagnostic procedures 
compared to approximately 0.20 E+6 Therapeutic procedures performed in the U.S 
during 2001.  The total number of Diagnostic procedures consists of three main 
categories: 0.29 E+06 FDG (Pet Scans), 5.83 E+06 Cardiology, and 8.08 E+06 Other.  
The detailed information used to correlate and cross-reference the number of 
procedures in each of these categories to specific isotopes is summarized in Table 3 
(listed in the Data Tables section at the end of this report).   
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4.0 APPLIED NUCLEAR SCIENCE DATA 
The data from the field of Applied Nuclear Science was obtained from R.E. Schenter in 
the form of a private communication.  Dr. Schenter has compiled a comprehensive list of 
111 isotopes and their applications from the field of Nuclear Medicine.  Note that most of 
these isotopes have been used in medical research projects, and are not commercially 
produced.  Therefore they are unlikely to be seen at ports of entry into the U.S.  
Nevertheless, this list is important to have as a reference because some of these 
isotopes may eventually find their way into the commercial markets. 
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6.0 DATA TABLES 
Table 2: Medical Data from Ref.1 
Exam 
R# 
Exam Name Radiopharmaceutical 
Product 
Isotope Activity 
(mCi) 
Exams 
in 2001 
Exams 
in 2002 
1 ACUTE Acutect Tc-99 20.0 2  
2 IN-111 Zevalin IN-lll ZEVALIN In-111 5.00 0 1 
3 Y-90 Zevaline Y-90 Zevaline Y-90 10.0 -- 
32.0 
0 1 
4 ADENOSINE Heart Perf. MYOVIEW Tc-99 22.0 204 151 
5 BONE Marrow Sulfur Colloid Tc-99 10.0 -- 
15.0 
2 4 
6 BONE SCAN MDP Tc-99 30.0 226 184 
7 BONE SCAN MDP Tc-99 30.0 499 416 
8 BONE SPECT MDP Tc-99 30.0 65 49 
9 BONE Three Phase MDP Tc-99 30.0 58 57 
10 BRAIN Imaging w/ Flow D.T.P.A. Tc-99 25.0 13  
11 BRAIN Ceretec Tc-99 25.0 51 33 
12 BREAST Lymphoscintigr Sulfur Colloid Tc-99 0.90 -- 
1.50 
20 21 
13 CESIUM 137 Implant CESIUM 137 Seeds Cs-137 ??? 2 1 
14 CISTERNOGRAPHY DTPA In-111 1.00 3 4 
15 DICOPAC Co-58/-57  0.0006 10  
16 DMSA D.M.S.A Tc-99 4.00 0 2 
17 DOBUTAMINE Heart Perf. Cardiolite Tc-99 22.0 14 4 
18 G.E. Reflux Sulfur Colloid Tc-99 0.50 9 4 
19 Gastric Emptying Sulfur Colloid Tc-99 1.00 44 57 
20 GATED Tc99m- Tc-99 20.0 -- 
30.0 
39 13 
21 GI Blood Loss U1traTag RBC Tc-99 20.0 19 19 
22 HEPATOBiliary  Hepatolite Tc-99 5.00 20 32 
23 HEPATOBILIARY Hepatolite Tc-99 5.00 187 180 
24 LIVERHEMANgioma U1traTag RBC Tc-99 20.0 -- 
30.0 
1 1 
***25       
26 LIVER/SPLEEN Microlite Tc-99 6.00 4 6 
27 LUNG MAA Tc-99 6.00 42 37 
28 LUNG VENT./DTPA D.T.P.A. Tc-99 35.0 -- 
40.0 
41 35 
29 LUNG VENT./ Xe133  Xe-133 10.0 0  
30 LYMPHOSCINTGRAPHY Microlite Tc-99 1.00 5 3 
31 MECKELS Tc99m Tc-99 10.0 1 6 
32 MIBI Rest Cardiolite Tc-99 22.0 2 60 
33 MIBI Stress Cardiolite Tc-99 22.0 0 43 
34 MIBI Stress Cardiolite Tc-99 22.0 1 20 
35 MYOVIEW Persanine MYOVIEW Tc-99 22.0 1  
36 MYOVIEW Rest MYOVIEW Tc-99 22.0 422 279 
37 MYOVIEW Stress MYOVIEW Tc-99 22.0 217 123 
38 NEOTECT NeoTect Tc-99 15.0 -- 
20.0 
1  
39 PARATHYROID Cardlolite Tc-99 25.0 12 13 
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Exam 
R# 
Exam Name Radiopharmaceutical 
Product 
Isotope Activity 
(mCi) 
Exams 
in 2001 
Exams 
in 2002 
40 PERITONEAL Sulfur Colloid Tc-99 3.00 -- 
5.00 
1  
41 PY-TEST C14 UREA C-14 UREA C-14 0.001 30 28 
42 PYP INFARCT PYP Tc-99 25.0 0 0 
43 QUADRAMET Quadremet Sm-153 36.0 -- 
140.0 
1 1 
44 RED Cell Mass Cr-51 Cr-51 0.075 7 11 
45 RENAL W/ LASIX MAG3 Tc-99 6.00 20 24 
46 RENOGRAM MAG3 Tc-99 6.00 9 4 
47 RENOGRAM w/ Captopril MAG3 Tc-99 6.00 18 14 
48 SCHILLINGS Co-57 Co-57 0.0005 7 33 
49 SCINTIMAMMOGRAPHY Cardiolite Tc-99 25.0 0 1 
50 SHUNT Patency V/P D.T.P.A. Tc-99 1.00 19 6 
51 SPECT Miscellaneous Ga-67 Ga-67 ??? 0 1 
52 STRONTIUM 89 RX Metastron Sr-89 4.00 1  
53 THYROID ABLATION I-131 I-131 30.0 18 13 
54 THYROID CA ABLATION I-131 I-131 34.0 -- 
150.0 
2 4 
55 THYROID 
Hyperthyroidism 
I-131 I-131 5.00 -- 
25.0 
48 15 
56 THYROID SCAN Tc99m Tc-99 5.00 143 63 
57 THYROID SCAN I-123 I-123 Caps I-123 0.40 13 75 
58 THYROID Uptake I-131 I-131 0.004 -- 
0.016 
154 67 
59 THYROID Uptake I-123 I-123 Caps I-123 0.20 11 62 
60 THYROID WB Iodine I-131 I-131 3 -- 
4.00 
17 23 
61 TL201 REST Tl-201 Tl-201 4.00 3 7 
62 TL201 24Hour SPECT Tl-201 Tl-201 ??? 0 0 
63 TL201 ADENOSINE Tl-201 Tl-201 3.50 0 0 
64 TL201 PERSANTINE TI-201 TI-201 3.50 0 0 
65 TL201 Reinjection Tl-201 Tl-201 1.00 -- 
2.00 
4 2 
66 TL201 Stress Treadmill TI-201 Tl-201 3.50 3 1 
67 TRACER SENT OUT Tc99m Tc-99 20.00 0 0 
68 Tumor Localization -M Cardiolite Tc-99 25.00 0 0 
69 Tumor Localization -G Ga-67 Ga-67 6.00 -- 
10.0 
3 7 
70 Tumor Localization -O In-111-0ctreoScan In-111 6.00 9 9 
***71       
72 Tumor Localization -T Tl-201 Tl-201 3.50 0 0 
73 Tumor LOCALZ. CEA-
SCA 
SEA-SCAN Tc-99 25.00 0 0 
74 URETERAL Reflux Tc99m Tc-99 1.00 1 1 
75 WHITE Cell / Indium In-111 WBC In-111 0.50 -- 
0.90 
13 21 
76 WHITE Cell / TC-HMPAO Ceretec Tc-99 8.00 -- 
25.0 
2 0 
***77 PET "FDG" F-18 8.00 -- 
20.0 
0 120 
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Table 3: Summary of Data from 2001 U.S. Market Survey of Products by Ref.2 
Page 13 of 18 
Market Product 
No. 
Product Name    
   Isotope Manufacturer Application (See Notes) 
Diagnostic 
- Cardiac 
1 Cardiolite Tc-99 BMS Cardio/Diag - MP 
 2 Myoview Tc-99 Amer. Cardio/Diag - MP 
 3 Thallium-201 Tl-201 BMS Cardio/Diag - MP 
 4 Thallium-201 Tl-201 Amer. Cardio/Diag - MP 
 5 Thallium-201 Tl-201 Mall. Cardio/Diag - MP 
 6 Tc-99 PYP Tc-99 Amer. Cardio/Diag - BP 
 7 Phosphotec Tc-99 Brac. Cardio/Diag - BP 
 8 Technescan 
PYP 
Tc-99 Mall. Cardio/Diag - BP 
 9 CIS-Pyro Tc-99 CIS Cardio/Diag - BP 
 10 Pyrolite Tc-99 CIS Cardio/Diag - BP 
 11 Cardiogen Rb-82 Brac. Cardio/Diag - MV 
      
Diagnostic 
- Other 
12 Sodium 
Chromate 
Cr-51 Mall. RBC  
(Tier-1 
Suppliers) 
13 *no name* Ga-67 Amer., BMS, 
Mall. 
Soft Tissue Tumor / 
Lymphoma 
 14 Sodium Iodine I-123 Amer., Mall. Thyroid 
 15 Human Serum 
Albmn 
I-125 Mall. Blood / Plasma Vol. 
 16 Chloride In-111 Amer., Mall. Labelling Agent 
 17 Oxine In-111 Amer. WBC / platelets 
 18 Pentetreotide In-111 Mall. Neuroendoctrine Tumors 
 19 Bicisate Tc-99 BMS Brain 
 20 Exametazine Tc-99 Amer. Cerebral Blood Flow / 
WBC 
 21 MAA Tc-99 Mall. Lung 
 22 Medronate Tc-99 Amer., Mall. Skeletal / Bone 
 23 Mertiatide Tc-99 Mall. Renal 
 24 Oxidronate Tc-99 Amer., Mall. Bone 
 25 Pentetate Tc-99 Amer., Mall. Kidney / Brain 
 26 Pyrophosphate Tc-99 Amer., Mall. Skeletal / Cardiac 
 27 RBC Tc-99 Mall. Blood Pool / GI 
 28 Sestamibi Tc-99 BMS Cardiac / Breast 
 29 Sdm. 
Glucoheptonat
e 
Tc-99 Mall. Kidney / Brain 
 30 Succimer Tc-99 Amer. Renal Parenchymal 
 31 Sulfur Colloid Tc-99 Amer. RC 
 32 *no name* Xe-133 Amer., BMS, 
Mall. 
Pulmonary / Lung 
Diagnostic 
- Other 
33 Cyanobalamin Co-57 Brac. Pernicious Anemia 
PIET-43741-TM-197 
 
(Tier-2 
Suppliers) 
34 Capromab 
Pendetide 
In-111 Cytg Prostate Cancer 
 35 Satumomab 
Pendetide 
In-111 Cytg Colorectal / Ovarian 
Cancer 
 36 Pentetreotide In-111 CIS CSF Kinetics 
 37 MIBG I-131 CIS, Drax. Pheochromocytomas / 
Neuroblastoma 
 38 Apcitide Tc-99 Brlx Acute Venous Thrombosis 
 39 Arcitumomab Tc-99 Immu Colorectal Cancer 
 40 Depreotide Tc-99 Brlx Pulmonary Mass 
 41 Disofenin Tc-99 CIS Hepatobiliary 
 21 MAA Tc-99 Brac., CIS Lung / Perfusion 
 42 Mebrofenin Tc-99 Brac., CIS Hepatobiliary 
 25 Pentetate Tc-99 Brac., CIS, 
Drax. 
Kidney / Brain 
 26 Pyrophosphate Tc-99 Brac., CIS Skeletal / Cardiac 
 29 Sodium 
Glucoheptonate 
Tc-99 Drax. Kidney / Brain 
 31 Sulfur Colloid Tc-99 CIS RC 
 32 *no name* Xe-133 Drax. Lung / Pulmonary 
Diagnostic - 
PET 
43 FDG F-18  PET Diagnostic 
Therapeutic-
Bone 
44 Quadramet Sm-
153 
 Bone Pain Palliation 
(55-60% of 
Therapy 
Sector) 
45 Metastron Sr-89  Bone Pain Palliation 
Therapeutic-
Thyroid 
46 *no name* I-131  Hyperthyroidism/Thyroid 
Cancer 
(40-45% of 
Therapy 
Sector) 
     
NOTES: 
Products listed Market Sector, then top-down by percent. 
Some products are supplied by more than one manufacturer. 
Application Key 
MP =>  Myocardial Perfusion  
BP =>  Blood Pool  
MV =>  Myocardial Viability  
RBC => Red Blood Cells  
WBC => White Blood Cells  
GI =>  Gastrointestinal  
RC =>  Reticuloendothelial Cells 
CSF =>   
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Table 4: Medical Isotope Application Data from Ref.3. 
ISOTOPE Half-Life APPLICATIONS 
Ac-225 10.0d Monoclonal antibody attachment used for cancer treatment (RIT), also parent of Bi-213. 
Ac-227 21.8y Parent of Ra-223 (Monoclonal antibody attachment used for cancer treatment (RIT). 
Am-241 432y Osteoporosis detection, heart imaging. 
As-72 26.0h Planar imaging, SPECT or PET. 
As-74 17.8d Positron-emitting isotope with biomedical applications. 
At-211 7.21h Monoclonal antibody attachment (alpha emitter) used for cancer treatment (RIT), used 
with F-18 for in vivo studies. 
Au-198 2.69d Cancer treatment using mini-gun (B), treating ovarian, prostate, and brain cancer. 
B-11 Stable Melanoma and brain tumor treatment. 
Be-7 53.2d Used in berylliosis studies. 
Bi-212 1.10h Monoclonal antibody attachment (alpha emitter) used for cancer treatment (RIT), 
cellular dosimetry studies. 
Bi-213 45.6m Monoclonal antibody attachment (alpha emitter) used for cancer treatment (RIT). 
Br-75 98m Planar imaging, SPECT or PET (C). 
Br-77 57h Label radiosentizers for Te quantization of hypoxia in tumors, and monoclonal antibody 
labeling. 
C-11 20.3m Radiotracer in PET scans to study normal/abnormal brain functions. 
C-14 5730y Radiolabeling for detection of tumors (breast, et al.). 
Ca-48 Stable  
Cd-109 462d Cancer detection (C), pediatric imaging (C). 
Ce-139 138d Calibrates high-purity germanium gamma detectors <medical application?>. 
Ce-141 32.5d Gastrointestinal tract diagnosis, measuring regional myocardial blood flow. 
Cf-252 2.64y Cervical, melanoma, brain cancer treatment. 
Co-55 17.5h Planar imaging, SPECT or PET (B). Used in PET imaging of damaged brain tissue after 
stroke. 
Co-57 272d Gamma camera calibration, should be given high priority, radiotracer in research and a 
source for X-ray fluorescence spectroscopy. 
Co-60 5.27y Teletherapy (destroy cancer cells), disinfect surgical equipment and medicines, 
external radiation cancer therapy (E). 
Cr-51 27.7d Medical, cell labeling and dosimetry. 
Cs-130 29.2m Myocardial localizing agent. 
Cs-131 9.69d Intracavity implants for radiotherapy. 
Cs-137 30.2y Blood irradiators, PET imaging, tumor treatment. 
Cu-61 3.35h Planar imaging, SPECT or PET (B). 
Cu-62 4.7m Positron emitting radionuclide (B), cerebral and myocardial blood flow used As-a tracer 
in conjunction with Cu 64 (B). 
Cu-64 12.7h PET scanning (C), planar imaging (C), SPECT imaging (C) dosimetry studies (C), 
cerebral and myocardial blood flow (C), used with Cu-62 (C), treating of colorectal 
cancer. 
Cu-67 61.9h Cancer treatment/diagnostics, monoclonal antibodies, radioimmunotherapy, planar 
imaging, SPECT or PET. 
Dy-165 2.33h Radiation synovectomy, rheumatoid arthritis treatment. 
Eu-152 13.4y Medical. 
Eu-155 4.73y Osteoporosis detection. 
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F-18 110m Radiotracer for brain studies (C), PET imaging (C). 
Fe-55 2.73y Heat source <medical application?>. 
Fe-59 44.5d Medical. 
Ga-64 2.63m Treatment of pulmonary diseases ending in fibrosis of lungs. 
Ga-67 78.3h Imaging of abdominal infections (C), detect Hodgkins/non-Hodgkins lymphoma (C), 
used with In-111 for soft tissue infections and osteomyelitis detection (C), evaluate 
sarcoidiodis and other granulomaous diseases, particularly in lungs and mediastiusim 
(C). 
Ga-68 68.1m Study thrombosis and atherosclerosis, PET imaging, detection of pancreatic cancer, 
attenuation correction. 
Gd-153 242d Dual photon source, osteoporosis detection, SPECT imaging. 
Ge-68 271d PET imaging. 
H-3 12.3y Labeling, PET imaging. 
I-122 3.6m Brain blood flow studies. 
I-123 13.1h Brain, thyroid, kidney, and myocardial imaging (C), cerebral blood flow (ideal for 
imaging) (C), neurological disease (Alzheimer's) (C). 
I-124 4.17d Radiotracer used to create images of human thyroid, PET imaging. 
I-125 59.9d Osteoporosis detection, diagnostic imaging, tracer for drugs, monoclonal antibodies, 
brain cancer treatment (I-131 replacement), SPECT imaging, radiolabeling, tumor 
imaging, mapping of receptors in the brain (A), interstitial radiation therapy 
(brachytherapy) for treatment of prostate cancer (E). 
I-131 8.04d Lymphoid tissue tumor/hyperthyroidism treatment (C), antibody labeling (C), brain 
biochemistry in mental illness (C), kidney agent (C), thyroid problems (C), alternative to 
Tl-201 for radioimmunotherapy (C), imaging, cellular dosimetry, scintigraphy, treatment 
of graves disease, treatment of goiters, SPECT imaging, treatment of prostate cancer, 
treatment of hepatocellular carcinoma, treatment of melanoma (A), locate osteomyelitis 
infections (A), radiolabeling (A), localize tumors for removal (A), treatment of spinal 
tumor (A), locate metastatic lesions (A), treAt-neuroblastoma (A), internal (systemic) 
radiation therapy (E), treatment of carcinoma of the thyroid (E). 
I-132 2.28h Mapping precise area of brain tumor before operating. 
In-111 2.81d Detection of heart transplant rejection (C), imaging of abdominal infections (C), 
antibody labeling (C) cellular immunology (C), used with Ga-67 for soft tissue infection 
detection and ostemyelitis detection (C), concentrates in liver, kidneys (C), high specific 
activity (C), white blood cell imaging, cellular dosimetry, myocardial scans, treatment of 
leukemia, imaging tumors. 
In-115m 4.49h Label blood elements for evaluating inflammatory bowel disease. 
Ir-191m 6s Cardiovascular angiography. 
Ir-192 73.8d Implants or "seeds" for treatment of cancers of the prostate, brain, breast, 
gynecological cancers. 
Kr-81m 13.3s Lung imaging. 
Lu-177 6.68d Heart disease treatment (restenosis therapy), cancer therapy. 
Mn-51 46.2m Myocardial localizing agent. 
Mn-52 5.59d PET scanning. 
Mo-99 65.9h Parent for Tc-99m generator used for brain, liver, lungs, heart imaging. 
N-13 9.97m PET imaging, myocardial perfusion. 
Nb-95 35d Study effects of radioactivity on pregnant women and fetus, myocardial tracer, PET 
imaging. 
O-15 122s Water used for tomographic measuring of cerebral blood flow (C), PET imaging (C), 
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SPECT imaging. 
Os-191 15.4d Parent for Ir-191m generator used for cardiovascular angiography. 
Os-194 6.00y Monoclonal antibody attachment used for cancer treatment (RIT). 
P-32 14.3d Polycythaemia Rubra Vera (blood cell disease) and leukemia treatment, bone disease 
diagnosis/treatment, SPECT imaging of tumors (A), pancreatic cancer treatment (A), 
radiolabeling (A). 
P-33 25d Labeling. 
Pb-203 2.16d Planar imaging, SPECT or PET (used with Bi-212) (B), monoclonal antibody 
immunotherapy (B), cellular dosimetry. 
Pb-212 10.6h Radioactive label for therapy using antibodies, cellular dosimetry. 
Pd-103 17d Prostate cancer treatment. 
Pd-109 13.4h Potential radiotherapeutic agent. 
Pu-238 2.3y Pacemaker (no Pu-236 contaminants). 
Ra-223 11.4d Monoclonal antibody attachment (alpha emitter) used for cancer treatment (RIT). 
Ra-226 1.60e3y Target isotope to make Ac-227, Th-228, Th-229 (Parents of alpha emitters used for 
RIT). 
Rb-82 1.27m Myocardial imaging agent, early detection of coronary artery disease, PET imaging, 
blood flow tracers. 
Re-186 3.9d Cancer treatment/diagnostics, monoclonal antibodies, bone cancer pain relief, 
treatment of rheumatoid arthritis, treatment of prostate cancer, treating bone pain. 
Re-188 17h Monoclonal antibodies, cancer treatment. 
Rh-105 35.4h Potential therapeutic applications: target neoplastic cells (e.g., small cell lung cancer) 
(A), labeling of molecules and monoclonal antibodies (A). 
Ru-97 2.89d Monoclonal antibodies label (C), planar imaging (C), SPECT or PET techniques (C), 
gamma-camera imaging. 
Ru-103 39d Myocardial blood flow, radiolabeling mircospheres, PET imaging. 
S-35 87.2d Nucleic acid labeling, P-32 replacement, cellular dosimetry. 
Sc-46 84d Regional blood flow studies, PET imaging. 
Sc-47 3.34d Cancer treatment/diagnostics (F), monoclonal antibodies (F), radioimmunotherapy (F). 
Se-72 8.4d Brain imaging, generator system with As-72, monoclonal antibody immunotherapy. 
Se-75 120d Radiotracer used in brain studies, scintigraphy scanning. 
Si-28 Stable Radiation therapy of cancer. 
Sm-145 340d Brain cancer treatment using I-127 (D). 
Sm-153 2.00d Cancer treatment/diagnostics (C), monoclonal antibodies (C), bone cancer pain relief 
(C), higher uptake in diseased bone than Re-186 (C), treatment of leukemia. 
Sn-117m 13.6d Bone cancer pain relief. 
Sr-85 65.0d Detection of focal bone lesions, brain scans. 
Sr-89 50d Bone cancer pain palliation (improves the quality of life), cellular dosimetry, treatment of 
prostate cancer, treatment of multiple myeloma, osteoblastic therapy, potential agent 
for treatment of bone metastases from prostate and breast cancer (E). 
Sr-90 29.1y Generator system with Y-90 (B), monoclonal antibody immunotherapy (B). 
Ta-178 9.3m Radionuclide injected into patients to allow viewing of heart and blood vessels. 
Ta-179 1.8y X-ray fluorescence source and in thickness gauging (might be a good substitute for 
Am-241). 
Ta-182 115d Bladder cancer treatment, internal implants. 
Tb-149 4.13h Monoclonal antibody attachment used for cancer treatment (RIT). 
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Tc-96 4.3d Animal studies with Tc-99m. 
Tc-99m 6.01h Brain, heart, liver (gastoenterology), lungs, bones, thyroid, and kidney imaging (C), 
regional cerebral blood flow (C), equine nuclear imaging (C), antibodies (C), red blood 
cells (C), replacement for Tl-201 (C). 
Th-228 720d Cancer treatment, monoclonal antibodies, parent of Bi-212. 
Th-229 7300y Grandparent for alpha emitter (Bi-213) used for cancer treatment (RIT), parent of Ac-
225. 
Tl-201 73.1h Clinical cardiology (C), heart imaging (C), less desirable nuclear characteristics than 
Tc-99m for planar and SPECT imaging (C), myocardial perfusion, cellular dosimetry. 
Tm-170 129d Portable blood irradiations for leukemia, lymphoma treatment, power source. 
Tm-171 1.9y Medical. 
W-188 69.4d Cancer treatment, monoclonal antibodies, parent for Re-188 generator. 
Xe-127 36.4d Neuroimaging for brain disorders, research for variety of neuropsychiatric disorders, 
especially schizophrenia and dementia, higher resolution SPECT studies with lower 
patient dose, lung imaging (some experts believe it is superior to Xe-133 in inhalation 
lung studies). 
Xe-133 5.25d Lung imaging (C), regional cerebral blood flow (C), liver imaging (gas inhalation) (C), 
SPECT imaging of brain, lung scanning, lesion detection. 
Y-88 107d Substituted for Y-90 in development of cancer tumor therapy. 
Y-90 64h Internal radiation therapy of liver cancer (C), monoclonal antibodies (C), Hodgkins 
disease, and hepatoma (C), cellular dosimetry, treating rheumatoid arthritis, treating 
breast cancer, treatment of gastrointestinal adenocarcinomas (A). 
Y-91 58.5d Cancer treatment (RIT), cellular dosimetry. 
Yb-169 32d Gastrointestinal tract diagnosis. 
Zn-62 9.22h Parent of Cu-62, a positron-emitter, used for the study of cerebral and myocardial blood 
flow. 
Zn-65 244d Medical. 
Zr-95 64.0d Medical. 
NOTES: 
A = June 1996 SNM Abstracts  
B = Holmes 91 
C = Herac 89 
D = Fairchild 87 
E = Everyone's Guide to Cancer Therapy (Dollinger, Rosenbaum, Cable), 1991 
F = SNM (Society of Nuclear Medicine) 
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